Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab nine months
/
Study Part 1:
All patients will receive 8 courses of GA101 + ibrutinib 420mg PO every 28 days
Study Part 2:
After evaluation at D1 of month 9:
If patients are in CR with BM MRD < 10-4, they will continue ibrutinib alone at a dose of
420mg daily If patients have BM MRD >10-4 whatever IWCLL 2008 responses or PR they will
receive four courses of GA101 + FC at 28-day intervals + Ibrutinib PO until final evaluation
of M16